Awards for “TEVA PHARMACEUTICALS USA, INC.”
25 awards on this page · sorted by amount · page 20
| Award ID | Recipient | Awarding agency | Amount | Start | End | NAICS | Description |
|---|---|---|---|---|---|---|---|
| SPE2DP21F2078 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-02-11 | 2021-02-23 | 325412 | 8507982416!ADENOVIRUS TYPE 4 A |
| SPE2DP21F1564 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $141.18K | 2021-01-14 | 2021-01-26 | 325412 | 8507916120!ADENOVIRUS TYPE 4 A |
| V797D9479 | TEVA PHARMACEUTICALS USA, INC. | Department of Veterans Affairs | $137.61K | 2011-04-14 | 2011-08-18 | 325412 | FUROSEMIDE TABLETS FOR PHARMACEUTICAL REPACKAGING PROGRAM |
| SPE2DP21F0378 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-11-03 | 2020-11-17 | 325412 | 8507773460!ADENOVIRUS TYPE 4 A |
| SPE2DP21F0377 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-11-03 | 2020-11-17 | 325412 | 8507773377!ADENOVIRUS TYPE 4 A |
| SPE2DP21F0136 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-10-19 | 2020-10-27 | 325412 | 8507719494!ADENOVIRUS TYPE 4 A |
| SPE2DP21F0135 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-10-19 | 2020-10-27 | 325412 | 8507719491!ADENOVIRUS TYPE 4 A |
| SPE2DP21F0134 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-10-19 | 2020-10-27 | 325412 | 8507719307!ADENOVIRUS TYPE 4 A |
| SPE2DP21F0132 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-10-19 | 2020-10-27 | 325412 | 8507719192!ADENOVIRUS TYPE 4 A |
| SPE2DP21F0131 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-10-19 | 2020-10-27 | 325412 | 8507719109!ADENOVIRUS TYPE 4 A |
| SPE2DP21F0129 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-10-19 | 2020-10-27 | 325412 | 8507719102!ADENOVIRUS TYPE 4 A |
| SPE2DP21F0125 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-10-19 | 2020-10-27 | 325412 | 8507718993!ADENOVIRUS TYPE 4 A |
| SPE2DP20F7226 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-09-21 | 2020-09-29 | 325412 | 8507666474!ADENOVIRUS TYPE 4 A |
| SPE2DP20F6743 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-08-19 | 2020-08-25 | 325412 | 8507594820!ADENOVIRUS TYPE 4 A |
| SPE2DP20F6740 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-08-19 | 2020-08-25 | 325412 | 8507594797!ADENOVIRUS TYPE 4 A |
| SPE2DP20F6739 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-08-19 | 2020-08-25 | 325412 | 8507594796!ADENOVIRUS TYPE 4 A |
| SPE2DP20F6737 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-08-19 | 2020-08-25 | 325412 | 8507594790!ADENOVIRUS TYPE 4 A |
| SPE2DP20F6269 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-07-23 | 2020-07-28 | 325412 | 8507542321!ADENOVIRUS TYPE 4 A |
| SPE2DP20F6219 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-07-22 | 2020-07-28 | 325412 | 8507538043!ADENOVIRUS TYPE 4 A |
| SPE2DP20F6216 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-07-22 | 2020-07-28 | 325412 | 8507538019!ADENOVIRUS TYPE 4 A |
| SPE2DP20F5518 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-06-17 | 2020-06-23 | 325412 | 8507472372!ADENOVIRUS TYPE 4 A |
| SPE2DP20F5517 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-06-17 | 2020-06-23 | 325412 | 8507472371!ADENOVIRUS TYPE 4 A |
| SPE2DP20F5514 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-06-17 | 2020-06-23 | 325412 | 8507472348!ADENOVIRUS TYPE 4 A |
| SPE2DP20F5013 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-05-21 | 2020-05-28 | 325412 | 8507395452!ADENOVIRUS TYPE 4 A |
| SPE2DP20F5012 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $135.75K | 2020-05-21 | 2020-05-28 | 325412 | 8507395450!ADENOVIRUS TYPE 4 A |